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Abstract
Objective: Bronchiolitis, one of the most common reasons for hospitalisation in young children, is particularly problematic
in Indigenous children. Macrolides may be beneficial in settings where children have high rates of nasopharyngeal bacterial
carriage and frequent prolonged illness. The aim of our double-blind placebo-controlled randomised trial was to determine
if a large single dose of azithromycin (compared to placebo) reduced length of stay (LOS), duration of oxygen (O2) and
respiratory readmissions within 6 months of children hospitalised with bronchiolitis. We also determined the effect of
azithromycin on nasopharyngeal microbiology.
Methods: Children aged #18 months were randomised to receive a single large dose (30 mg/kg) of either azithromycin or
placebo within 24 hrs of hospitalisation. Nasopharyngeal swabs were collected at baseline and 48hrs later. Primary
endpoints (LOS, O2) were monitored every 12 hrs. Hospitalised respiratory readmissions 6-months post discharge was
collected.
Results: 97 children were randomised (n = 50 azithromycin, n = 47 placebo). Median LOS was similar in both groups;
azithromycin = 54 hours, placebo = 58 hours (difference between groups of 4 hours 95%CI -8, 13, p = 0.6). O2 requirement
was not significantly different between groups; Azithromycin = 35 hrs; placebo = 42 hrs (difference 7 hours, 95%CI -9, 13,
p = 0.7). Number of children re-hospitalised was similar 10 per group (OR= 0.9, 95%CI 0.3, 2, p = 0.8). At least one virus was
detected in 74% of children. The azithromycin group had reduced nasopharyngeal bacterial carriage (p = 0.01) but no
difference in viral detection at 48 hours.
Conclusion: Although a single dose of azithromycin reduces carriage of bacteria, it is unlikely to be beneficial in reducing
LOS, duration of O2 requirement or readmissions in children hospitalised with bronchiolitis. It remains uncertain if an earlier
and/or longer duration of azithromycin improves clinical and microbiological outcomes for children. The trial was registered
with the Australian and New Zealand Clinical Trials Register. Clinical trials number: ACTRN12608000150347. http://www.
anzctr.org.au/TrialSearch.aspx.
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Introduction
Worldwide, bronchiolitis remains one of the most common
reasons for hospitalisation of children [1]. Over 3 million children
are diagnosed with bronchiolitis annually [2,3]. The incidence of
bronchiolitis is higher in some populations, including Alaskan
Native and Indigenous Northern Territory (NT) infants [1]. In the
latter group, hospitalisation rates for bronchiolitis are higher [4]
(352 vs. 62.6 per 1000) and infections are more severe than non-
Indigenous children [5].
Bronchiolitis is a clinical syndrome that is diagnosed in children
up to 24 months of age [6–8]. The most common infecting virus,
respiratory syncytial virus (RSV) occurs in 50–80% of cases, [9]
although an increasing number of viruses (e.g. human rhinoviruses
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(HRV), coronaviruses, bocavirus), [10,11] including multiple
infections [12] are being identified.
Current recommended therapies in hospitalised children are
limited to oxygen (O2), fluids and hypertonic saline nebulisation
[7]. Antibiotics are rarely advocated in the management of
bronchiolitis unless the illness is very severe or when a secondary
bacterial infection is suspected [13]. However, semi-synthetic
macrolides (e.g. azithromycin, clarithromycin) which have im-
muno-modulatory, and/or anti-microbial properties [14] and in-
vitro anti-viral effects, [15] which may be beneficial in children with
bronchiolitis and high nasopharyngeal carriage rates of bacteria.
Three randomised placebo-controlled trials (RCTs) have been
published and these RCTs used different doses and duration of
macrolides to treat hospitalised bronchiolitis [16] [17,18]. These
studies also differed in affluence of settings which may reflect
differences in the frequency and severity of acute respiratory
infections in these populations [19]. Thus not surprisingly, results
from the existing RCTs differed in the effect on reducing length of
hospitalisation and O2 requirement. A Turkish [17] trial reported
improved clinical outcomes. In comparison a European [16] and a
Brazilian [18] trials showed no improvement.
Bacterial infections in children with RSV positive acute lower
respiratory infections range from 3.5% to 31% [2,20,21]. The
higher rate is more likely in less-affluent settings and/or with those
with more severe disease [22–24]. Viral-bacterial co-infections are
more likely when the upper airways are densely colonised with
bacteria or during repeated infections [25]. In the NT, children
have early acquisition of bacteria in the nasal space [26]. This is
more likely to be similar to Turkey where high rates of pneumonia
and bronchiectasis are also reported [22]. Thus, we conducted a
RCT on children hospitalised with bronchiolitis. Our primary
objective was to determine whether a single large dose of
azithromycin (compared to placebo) reduced length of stay
(LOS) and duration of O2 requirement in children hospitalised
Table 1. Demographic and clinical characteristics of 96 patients randomized to treatment of Azithromycin (n = 50) or placebo
(n = 46) and by ethnicity.
Azithromycin (n =50) Placebo (n =46)
Indigenous
(31)
Non Indigenous
(19) TOTAL (50)
Indigenous
(30)
Non Indigenous
(16)
TOTAL
(46)
Age in months 5 (3–8) 5.6 (1.5–11) 5.3 (3–9.4) 5.5 (3.1–8.5) 5 (2.3–8.5) 5 (3–8.5)
Age #6 months 19 (61%) 9 (47.3%) 28 (56%) 18 (60%) 9 (53%) 27 (59%)
Boys 23 (74%) 11 (58%) 34 (68%) 19 (63%) 12 (75%) 31 (67%)
Gestational age (weeks) 39 (35–40) 38.3 (37–40) 39 (36–40) 38 (36–39.1) 39.2 (38.1–40) 38 (36–40)
Birth weight (kg) 3.15 (1.9–3.4) 3.38 (2.87–3.78) 3.1 (2.5–3.6) 2.82 (2.32–3.0) 3.36 (2.72–3.46) 2.87 (36–40)
Number from remote areas 19 (61%) 4 (21%) 23 (46%) 26 (87%) 3 (19%) 29 (63%)
Currently breastfed 11 (35%) 13 (68%) 24 (48%) 7 (23%) 7 (44%) 14 (63%)
Mother smoked during pregnancy 20 (65%) 2 (11%) 22 (44%) 17 (57%) 3 (19%) 20 (43.5%)
Exposed to household smoke 20 (65%) 3 (16%) 23 (46%) 24 (80%) 5 (31%) 29 (63%)
Symptoms present upon admission
Nasal discharge 27 (87%) 16 (84%) 43 (86%) 23 (77%) 13 (81%) 36 (78%)
Cough 31 (100%) 19 (100%) 50 (100%) 30 (100%) 16 (100%) 46 (100%)
Breathing difficulties 31 (100%) 19 (100%) 50 (100%) 29 (97%) 16 (94%) 44 (96%)
Poor feeding 15 (48%) 15 (79%) 30 (60%) 10 (33%) 16 (100%) 26 (57%)
Lethargy 16 (52%) 11 (58%) 27 (54%) 19 (63%) 11 (69%) 30 (65%)
Fever uC 37 (36.3–37.2) 37 (36–37) 37 (36.2–37.1) 37 (36.3–37) 37 (36.3–38) 37 (36.3–37.1)
Antibiotics prescribed 27 (87%) 9 (47%) 36 (72%) 25 (83%) 7 (44%) 32 (70%)
Supplemental IV fluid administered 12 (39%) 7 (37%) 19 (38%) 12 (40%) 7 (44%) 19 (41%)
CXR taken 30 (97%) 14 (74%) 44 (54%) 27 (90%) 11 (69%) 38 (46%)
Co morbidities
Otitis Media 7 (23%) 5 (26%) 12 (24%) 3 (10%) 1 (6%) 4 (9%)
Skin infection 8 (26%) 2 (11%) 10 (20%) 9 (30%) 1 (6%) 10 (22%)
Anaemia 7 (23%) 1 (5% 8 (16%) 2 (7%) 1 (6%) 3 (7%)
Failure to Thrive 1 (3%) 0 (%) 1 (2%) 1 (3%) 0 (%) 1 (2%)
Lobar Pneumonia/Collapse
on CXR
8 (26%) 1 (5%) 9 (18%) 5 (17%) 0 (%) 5 (11%)
Other 1 (3%) 0 (0%) 1 (2%) 3 (13%) 2 (13%) 6 (13%)
Median and IQR (25–75) for continuous variables. Actual numbers for categorical variables and percentages.
NB: Missing variables described.
Azithromycin: Gestational age = 3 (6%). Birth weight = 6 (12%). Mother smoked during pregnancy = 3 (6%). Exposure to household smoke = 2 (4%), Placebo:
Gestational age: = 2 (4%). Birth weight = 3 (6.5%).
Indigenous children: Gestational age = 2 (3.3%). Birth weight = 4 (6.5%). Mother smoked during pregnancy = 2 (3%). Exposure to household smoke = 1 (1.6%): Non
Indigenous children: Gestational age: = 3 (8.6%). Birth weight = 5 (14.3%) Mother smoked during pregnancy = 1 (3%). Exposure to household smoke = 1 (3%).
doi:10.1371/journal.pone.0074316.t001
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with moderate to severe bronchiolitis. We also determined the
influence of azithromycin on the incidence of respiratory
readmissions and presence of bacteria and viruses in the
nasopharynx.
Methods
Study design
Our double-blinded, placebo-controlled, RCT was conducted
at the Royal Darwin Hospital between June 2008 and December
2011 and The Townsville Hospital between October 2010 and
December 2011.
Trial registration
The trial was registered with the Australian and New Zealand
Clinical Trials Register. Clinical trials number:
ACTRN12608000150347.
Ethics statement
The study was approved by the Human Research Ethics
Committee of the Northern Territory Department of Health and
Menzies School of Health Research (HREC 07/60) and The
Townsville Health Service District Human Research Ethics
Committee (HREC/10/QTHS/9). Individual written informed
consent was obtained from children’s parents or legal guardian.
Participants
Children were enrolled if they were #18 months, admitted with
a clinical diagnosis of bronchiolitis (according to standardised
hospital protocols; #18 months, with cough and coryza, wheezing
+/2 crackles, respiratory distress with both tachypnoea (respira-
tory rate .50 beats/min) and retractions), required supplemental
O2 and consented within 24 hrs of hospitalisation. Children were
excluded if they had: severe disease (admitted to intensive care
unit); chronic lung disease, congenital heart disease, contraindica-
Figure 1. CONSORT trial overview.
doi:10.1371/journal.pone.0074316.g001
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tions to macrolide use (e.g. liver dysfunction, hypersensitivity),
diarrhoea (.2 stools of watery consistency more than normal
pattern), received macrolides (in last 7-days), or clinical and
radiological features consistent with a primary diagnosis of
pneumonia [27] at time of randomisation.
Protocol and interventions used across both sites
Study staff visited the paediatric wards twice daily to assess
newly admitted children. After consent, children were randomised
to receive a single large dose of oral liquid azithromycin (30 mg/
kg) or placebo suspension (equal volume). The placebo suspension
was made up of confectioner’s Sugar, Hydroxypropyl Cellulose,
Xanthan Gum, Syloid 244, Sodium Phosphate Tribasic, Imitation
Vanilla Creamy Flavour, Black Cherry Flavour, Quinine Sulphate
(ground Quinate 300 mg Tablets). Children were managed by the
paediatric team of each hospital according to the same clinical
protocol for bronchiolitis (e.g. criteria for commencement and
weaning of O2) that was standardised .6 months before
commencement of the trial. Children were allowed to receive
concurrent medications specified by the attending physician,
except macrolide antibiotics. The protocol for this trial and
supporting CONSORT checklist are available as supporting
information; see Checklist S1 and Protocol S1.
Randomisation, allocation and blinding
Randomisation was stratified by age (#6 or .6 months),
ethnicity (Indigenous or non-Indigenous) and site (Darwin or
Townsville). Randomisation was by computer generated permuted
blocks and treatment allocation concealed by opaque stickers.
Upon enrolment, children were assigned the next treatment on the
appropriate stratified list. Neither the study team (researchers,
hospital staff) nor parents were aware of the assigned treatment
group until the end of the trial.
The placebo medication was manufactured by the Institute of
Drug Technology Australia Limited (Melbourne, Victoria). It had
a similar smell and taste to active azithromycin. Azithromycin
(Pfizer, Australia) was repackaged by IDT. Both medications were
prepared as powder in identical opaque bottles and sealed with an
aluminium foil.
Figure 2. Length of stay (LOS) in hospital – Azithromycin Vs
Placebo and Ethnicity.
doi:10.1371/journal.pone.0074316.g002
Figure 3. Time on Oxygen (O2) in hospital – Azithromycin Vs
Placebo and Ethnicity.
doi:10.1371/journal.pone.0074316.g003
Figure 4. Time to first readmission – Azithromycin Vs Placebo.
doi:10.1371/journal.pone.0074316.g004
Figure 5. Time to first readmission – Indigenous Vs Non-
Indigenous.
doi:10.1371/journal.pone.0074316.g005
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Clinical assessment and outcome measures
Standardised data collection forms were used to record
demographic, medical history and clinical data from each child
(table-1). This included O2 requirement and level, respiratory rate,
temperature and heart rate. Other therapies (intravenous fluids,
antibiotics) and routine investigations (full blood count and chest x-
ray) were also documented.
Children enrolled in the study were assessed twice daily by the
attending doctor (blinded and not an investigator) for clinical signs
inconsistent with bronchiolitis and associated with known azith-
romycin side effects. Outcome measures were collected every
12 hours until the study endpoint was reached. The primary
endpoints were: LOS for respiratory illness and duration of O2
requirement. LOS was defined as time from admission to time for
‘ready for discharge’ (Sp02 consistently .94% in air for .16 hrs)
and feeding adequately. ‘Ready for discharge’ differed from LOS,
as discharge from hospital in our setting is often delayed due to
other social factors, especially in children from remote Indigenous
communities. Other outcomes were (i) any respiratory related
readmissions within 6 months of discharge and (ii) identification of
respiratory viruses and bacterial pathogens. Adverse events were
monitored by study staff every 12 hours until discharge. Respira-
tory readmissions were collected from the medical charts; as there
these children had no access to any other hospitals in the region,
this is a reliable outcome.
Specimen collection and process
A nasopharyngeal swab (NPS) was taken prior to administration
of study medication and 48 hrs later (or at discharge). NPS were
placed in skim milk tryptone glucose glycerol broth media and
were transferred on ice stored at 280uC in accordance to
published guidelines [28,29].
Assessment for viruses and atypical bacteria were described
previously [30–32]. Nucleic acids were extracted from 0.2 ml of
each NPS using the High Pure Viral Nucleic Acid kit (Roche
Diagnostics, Australia), according to the manufacturer’s instruc-
tions. Polymerase Chain Reaction (PCR) methods were used to
detect RSV (A and B), adenovirus, parainfluenza (1, 2, 3),
influenzavirus (A and B), HRV and enterovirus, coronaviruses,
bocavirus type 1, human metapneumovirus (hMPV), KI (KIPyV)
and WU (WUPyV) polyomaviruses, Chlamydophila pneumoniae and
Mycoplasma pneumoniae. For bacterial analysis, NPS were thawed
and 10 mL aliquots cultured overnight on selective media at 37uC
in 5% CO2; identification of Streptococcus pneumoniae, Haemophilus
influenzae, Moraxella catarrhalis and Staphylococcus aureus used estab-
lished techniques as previously described [26,28,33].
Statistical methods
We formally compared baseline characteristics of Indigenous vs.
non-Indigenous children, with appropriate statistical tests. We did
not formally do this between treatment groups in accordance with
current CONSORT recommendations (available http://www.
consort-statement.org/consort-statement/13-19-results/item15_
baseline-data/. Accessed 28th June 2013). Our pre-specified
analysis plan, stated that non parametric methods be used if
Table 2. Subgroup analysis of LOS and time on O2 by ethnicity and age.
Azithromycin Placebo Difference 95% CI
(placebo-Azithromycin)
Length of Stay (LOS) median hours
Ethnicity
Indigenous 57 61 3 (213, 20)
Non Indigenous 46 54 4.5 (211, 13)
Age
,6 months 63 61 2.3 (218,19)
.6 months 47 51 0.7 (29, 11)
Time on oxygen (O2) median hours
Ethnicity
Indigenous 39 47 4 (212, 22)
Non Indigenous 30 36 4 (217, 12)
Age
,6 months 46 43 2 (218,19)
.6 months 30 32 0.7 (29, 12)
doi:10.1371/journal.pone.0074316.t002
Figure 6. Frequency of viruses detected in NPS – Baseline and
48 hours.
doi:10.1371/journal.pone.0074316.g006
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data were not normally distributed. Data were presented as
medians and interquartile range (IQR) for LOS and O2.
Differences between groups were tested using the Mann-
Whitney test. A 95% confidence interval (CI) was obtained for
the difference in medians between treatment groups [34].
Subgroup analysis was performed by ethnicity (Indigenous vs.
non-Indigenous) and by age (#6 and .6 months). Differences
in proportions were tested with Fisher’s exact test. We looked at
time to readmission within 6 months of hospital discharge using
Kaplan-Meier survival plots.
Sample size
We calculated that a total sample of 92 children (equal numbers
of Indigenous and non-Indigenous children recruited) would
provide 90% power to detect a difference in the mean LOS of
24 hrs between each treatment for each ethnic group at the 5%
significance level assuming the standard deviation was 24 hrs in
each group. This study was underpowered to detect differences in
rates of readmission between treatment groups.
Results
We recruited 97 children and data from 96 children were
analysed (Figure 1). The major reason why 450 children did not
meet the inclusion criteria was they did not require supplemental
O2 or were admitted over the weekend. During recruitment, 21
children admitted into intensive care were excluded; 17 were
Indigenous. One participant was excluded from the analysis of
primary outcomes; they had received a macrolide in the previous
7 days (this child was randomised to placebo). This child was
included in the analysis of secondary outcomes. Of the 96
remaining children, demographic and clinical characteristics were
similar between the treatment groups (Table-1). No children
received steroids during hospitalisation. Of the cohort, 10 children
were previously hospitalised for a respiratory episode, all were
Indigenous; 3 in azithromycin group and 7 in placebo group.
When data were grouped by ethnicity, a higher proportion of
Indigenous children lived in remote areas (n = 45, 74%;
p=,0.001), were exposed to cigarette smoke during pregnancy
(n = 37, 61%; p=,0.001), or in their household (n = 44, 72%;
p=,0.001). They were more likely to have coexisting co-
morbidities (i.e. skin infections (n = 17, 28%; p= 0.02) or
secondary pneumonia (n = 13, 21%; p= 0.01). More Indigenous
children (n = 34, 56%, p=,0.001) received antibiotics prior to
hospitalisation. The antibiotics given were ceftriaxone (n= 14,
41%), procaine penicillin (n = 7, 21%) and amoxicillin (n = 5,
15%). In hospital, additional antibiotics were more often
prescribed in Indigenous children (n= 52, 85%, p=,0.001)
(Table-1).
LOS was similar in both treatment groups. The median LOS in
the azithromycin group was 54 hrs, compared to 58 hrs in the
placebo group (difference between groups of 4 hrs, 95%CI 28,
13, p = 0.6), figure 2. The median time on O2 in the azithromycin
group was 35 hrs, compared to 42 hrs in the placebo group (i.e.
reduction of 7 hrs 95%CI 29, 13, p = 0.7), figure 3. No child
required admission into intensive care and there were no adverse
or serious adverse events.
All children contributed to readmission data. There was no
significant difference in the number of respiratory readmissions
within 6 months (10 per group, OR=0.9, 95%CI 0.3, 2, p= 0.8)
or time to readmission (logrank p= 0.9) between treatment groups
(figure 4). 70% of children readmitted, were reported to have a
wheeze-associated illness.
Indigenous children (n= 61) had longer LOS; median 59 hrs
compared to 51 hrs in non-Indigenous children (n= 35) (difference
of 8 hrs, 95%CI -25, 1.5, p = 0.07). This was similar with duration
of O2; 43 hrs in Indigenous children and 35 hrs in non-Indigenous
children (difference of 8 hrs 95%CI -22, 1.4, p = 0.08). A higher
proportion of Indigenous children were readmitted for a
respiratory illness (n = 16 (26%) compared to non-Indigenous
children (n= 4 (11%)), difference 15% (95%CI 0, 30%) p= 0.05.
Indigenous children were more likely to be re-hospitalised earlier
(Indigenous n= 16, non-Indigenous n= 4, OR=2.8, 95% CI 0.9,
8.8), logrank p= 0.08 (figure 5). There was no evidence that the
difference in either LOS or O2 between treatment groups varied
according to ethnicity or age (table-2).
Viral and bacteria data
All but one child had a baseline NPS. NPS could not be
obtained on all participants at 48 hrs due to discharge occurring
during evenings or weekends. One participant’s family withdrew
consent for NPS.
At baseline, viruses were not detected in 23 (24%) participants.
One or more virus was detected in 54 (56%) children. Two or
more viruses were detected in 19 (20%) of children. RSV was the
most common (n= 48, 50%), followed by HRV (n= 16, 17%),
hMPV (n= 5, 5%) and coronavirus (n = 5, 5%). Figure 6 depicts
the frequency of virus detection at baseline and 48hrs. There was
no reduction in the mean number of viruses detected per child
from baseline to 48hrs; azithromycin 1.0 to 0.8 (95% CI20.2, 0.6,
n = 34), placebo 0.9 to 1.0 (95% CI 20.3, 0.2, n = 37).
Table-3 summarises NPS bacteria detected at baseline and
48 hrs. A reduction in the mean number of respiratory bacteria
was detected per child; in the azithromycin group from 1.2 to 0.5
Table 3. Bacteria outcomes at pre treatment (baseline) and post treatment (48 hours).
Azithromycin Placebo Azi vs. Placebo
Baseline 48 hours Baseline 48 hours 48 hours
P value
Nasal carriage of pathogens N=49 N=34 N=46 N=37
Streptococcus pneumoniae 9 (18%) 2 (6%) 15 (33%) 7 (19%) 0.15
Haemophilus influenzae 18 (37%) 3 (9%) 18 (39%) 10 (27%) 0.06
Moraxella catarrhalis 21 (43%) 2 (6%) 16 (35%) 12 (32%) 0.006
Staphylococcus aureus 4 (8%) 1 (3%) 4 (9%) 1 (3%) 1.00
doi:10.1371/journal.pone.0074316.t003
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bacteria (difference 0.7 95%CI 0.25, 1.1, p= 0.01), and zero
change in the placebo group; 1.3 to 1.3 bacteria.
Compared to baseline NPS, children who received azithromy-
cin alone (n= 14) (i.e. received no additional antibiotics in hospital)
were less likely to have S. pneumoniae (3/14, vs. 0/11), M. catarrhalis
(5/14 vs. 1/11), H. influenzae (6/14 vs. 1/11), and Staphylococcus
aureus (1/14 vs.0/11) at 48 hrs. 3/14 children did not have NPS at
48 hrs.
Discussion
We found that a large single dose of azithromycin (compared to
placebo), did not have large clinical effects on LOS, length of O2
requirement or readmission within 6 months of discharge. Azithro-
mycin reduced the proportion of children with respiratory bacteria
in their NPS but had no significant effect on viral detection by PCR.
Of the 3 published RCTs on macrolides to treat hospitalised
children with bronchiolitis, [16–18] only one [17] reported
improved clinical effects i.e. reduced LOS, duration of O2
requirement and lower readmission rates. Our findings are similar
to the other two trials [16,18] showing that a single dose
azithromycin does not shorten LOS and O2 requirement.
However, methodological differences among trials need to be
considered. One of the larger trials [16] included only children
with RSV-confirmed bronchiolitis, thus limiting generalisation to
bronchiolitis caused by other pathogens. Other differences
included: age, ethnic populations, concurrent use of antibiotics,
treatment practices and macrolide type, dose and duration. The
immunomodulatory difference between azithromycin and clarith-
romycin may also account for the differential results between
Tahan et al’s study [17] with ours and the other 2 RCTs [16,18].
For example, azithromycin increased the production of IL-10
whereas clarithromycin inhibited the production of IL-6 by
dendritic cells in animal work [35]. Tahan and colleagues [17]
used a daily dose for 3-weeks of clarithromycin, but ours like
Kneyber et al [16,18] (7-day daily dose) used a short course of
azithromycin. However, Tahan et al’s [17] study had very small
numbers (n = 21) and high attrition. Thus, it remains unknown if a
longer course of azithromycin may be effective in reducing
readmission rates.
Of the published RCTs on macrolides for bronchiolitis in
children, our patient profile is most like that of the Turkish study
[17]. However, unlike the Turkish RCT, [17] we did not find a
beneficial effect of azithromycin on clinical outcomes. Possibly
contributory reasons include the very high concomitant use of
antibiotics in our group; different treatment regime used the
density of bacterial carriage and secondary co-morbidities. The
common use of antibiotics in children with bronchiolitis in our
setting relates to the high rates of concomitant infections among
children. A similar treatment practice occurs in Alaskan children
[1]. 56% of Indigenous children in our trial received antibiotics
before admission and 87% during hospitalisation. While the use of
antibiotics is common practice in such settings, its effectiveness and
possibly increased adverse events remains unknown. Ideally
concurrent antibiotics should have been disallowed in our study
but it was not possible to alter clinicians’ practice and our a priori
protocol allowed the concurrent use of antibiotics other than
macrolides.
We used a single large dose of azithromycin, which is equivalent
to one week of treatment for several reasons [36]. In our setting,
early (as early as 2-weeks of age) nasopharyngeal colonisation of
respiratory pathogens occurs in Indigenous children [37]. Azith-
romycin potentially has a beneficial microbiological effect on these
pathogens [36]. Azithromycin also has the benefit of a long half life
and tissue penetration requiring less frequent dosing, compared to
other antibiotics [36]. This is important in our setting where
adherence to treatment regimes can be challenging.
While our trial did not find significant differences between
treatment groups for clinical outcomes, our study had some novel
data. Firstly, none of the published RCTs on macrolides for
children with bronchiolitis report data on the impact on viral
detection or bacterial carriage. As viruses were identified by PCR,
it is not surprising no difference in viral detection were found at
48 hrs (although azithromycin may have some anti-viral effect)
[15]. Future research should look at the impact of azithromycin on
viral load/copies. While our numbers were small, we showed a
significant difference in the mean number of respiratory bacteria
per child; from 1.2 to 0.5 bacteria (difference 0.7 95%CI 0.25, 1.1,
p = 0.01) in the azithromycin group. This is important in our
setting as NPS carriage of respiratory pathogens (e.g. S. pneumoniae,
H. influenzae, M. catarrhalis) are among the highest reported globally
(over 80%), compared to non-Indigenous children (50%) [26].
Secondly, our study provides a clinical picture of hospitalised
cases of bronchiolitis in different geographical and ethnic groups in
Northern Australia, where acute respiratory infections may be one
precursor of high rates of chronic respiratory illness [5,38] This is
the first data published, showing NPS detection of viruses and
bacteria from Indigenous children hospitalised with bronchiolitis.
Wheezing and bacterial infections in young children have been
shown to be associated in one prospective cohort study [39]. Thus
our data may have implications in settings, where acute and
chronic respiratory diseases are particularly prevalent and more
severe, including Alaska and New Zealand [40–42].
We found that Indigenous children exhibited longer LOS, O2
requirement and earlier time to hospital readmission than non-
Indigenous children. The most likely reason why the latter aspects
are different from our previous study [5] is because we excluded
children managed in intensive care. In our cohort, Indigenous
children were more likely to be readmitted for another respiratory
illness. This is not surprising as Indigenous children in the NT are
5 times more likely to be hospitalised for pneumonia and influenza
than non-Indigenous children [43]. Whether readmission is related
to the insult from bronchiolitis can only be postulated. Recurrent
hospitalisation for respiratory illness is an independent risk factor
for developing bronchiectasis and/or respiratory dysfunction in
adulthood [44,45]. In our region, bronchiectasis affects 1 in every
68 Indigenous children [46]. In the follow up of our cohort, 6/61
(10%) Indigenous children (3 in azithromycin group, 3 in placebo
group) have subsequently been diagnosed with bronchiectasis and
an additional 4 children are awaiting chest scans.
The prevalence of readmission for a respiratory illness within 6-
months in our trial was 21%; 70% had a wheezing illness. This
was similar to the Turkish trial at 24% (53% were wheezing) [17].
The two most common viruses found in our cohort, RSV and
HRV have been implicated for ongoing wheezing [47–50]. New
Zealand data have also recently described high prevalence (70%)
of on-going intermittent wheeze 12-months post hospitalisation
with acute lower respiratory infections [41]. In addition, wheezing
and persistent cough can also be problematic post acute
bronchiolitis [17]. Our trial (and the other published RCTs of
macrolides for acute bronchiolitis) did not assess this, a known
clinical research gap [7,51].
Despite providing new data, there are other several limitations
to our study, in addition to the concurrent use of antibiotics.
Having older children increased the risk of including asthma prone
children. We also did not limit to the first bronchiolitis admission.
Removing the children with recurrent disease in a secondary
analysis made no difference to study outcomes. As our study was
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limited to a single dose, it remains uncertain if any macrolides, or a
longer macrolide treatment course, is beneficial in high risk
children who do not receive any other antibiotics. Only having
two sites, may also affect the generalisability of the results.
Conclusion
In children hospitalised with moderate to severe bronchiolitis
and requiring supplemental O2, we found that a large single dose
of azithromycin (compared to placebo) did not have any clinical
benefit to reduce LOS, duration of O2 requirement or readmission
rates within 6 months of hospital discharge. Azithromycin reduced
the proportion of bacterial carriage, but had no significant effect
on reducing proportion of viruses. Further research is required to
determine whether earlier administration and longer duration of
azithromycin is beneficial to improve the clinical and microbio-
logical outcomes of acute bronchiolitis, associated co-morbidities
and prevent ongoing respiratory morbidity in this population.
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